by Shoot To Thrill Media | Oct 22, 2025 | Crohn’s Disease
Medical Review: Dr. Gerald Mastaw, MD – Board-Certified Physician
Last Updated: October 2025
What Is Crohn’s Disease?
Crohn’s disease is a chronic inflammatory bowel disease (IBD) that causes ongoing inflammation anywhere along the gastrointestinal (GI) tract — most often the small intestine and the beginning of the large intestine.
This inflammation can lead to pain, fatigue, and poor nutrient absorption.
Common Symptoms
- Abdominal pain and cramping
- Persistent diarrhea or urgent bowel movements
- Unintended weight loss
- Fatigue or low energy
- Fever during flare-ups
- Nutritional deficiencies from poor absorption
Possible Risk Factors
- Family history of IBD
- Overactive or misdirected immune response
- Environmental triggers such as diet, stress, or smoking
Crohn’s symptoms often cycle between flare-ups and remission, which can make long-term management challenging.
Conventional Approaches to Treatment
While there’s currently no cure, standard care focuses on controlling inflammation and preventing complications.
Medications
- Corticosteroids – to quickly reduce inflammation during flare-ups
- Immunosuppressants – to calm the immune system
- Biologic agents – to block inflammatory pathways (e.g., anti-TNF drugs)
Lifestyle & Nutrition
- Identifying and avoiding food triggers
- Eating smaller, more frequent meals
- Staying hydrated and supplementing nutrients as needed
Surgery
- Removing severely damaged intestinal segments
- Treating strictures, abscesses, or fistulas
- Typically reserved for patients who don’t respond to medication
Even with the best care, many patients experience relapses or side effects that affect quality of life — leading some to explore regenerative approaches.
Regenerative Medicine and Crohn’s Disease
Regenerative medicine, particularly using umbilical cord tissue–derived mesenchymal stem cells (UCT-MSCs), is being studied as a novel way to calm inflammation and support intestinal repair.
How MSC Therapy May Help
- Regulates overactive immune responses
- Reduces chronic inflammation in the intestinal wall
- Encourages tissue regeneration and mucosal healing
- Improves nutrient absorption by restoring gut lining integrity
- May lower dependence on steroids or immune-suppressing drugs
Preliminary research suggests that stem-cell-based therapy may lead to:
- Fewer flare-ups
- Improved intestinal healing on imaging and endoscopy
- Enhanced overall well-being and energy
⚠️ Note: MSC therapy for Crohn’s disease is investigational and not FDA-approved. However, clinical evidence continues to expand showing encouraging safety and efficacy results.
Recent Advances in Regenerative Medicine for Crohn’s Disease
2025 – Stem Cell Educator Therapy in Long-Term Crohn’s
Title: Clinical, Immunological, Radiographic, and Pathologic Improvements in a Patient with Long-Standing Crohn’s Disease After Receiving Stem Cell Educator Therapy
Date: July 28, 2025
Link: MDPI – International Journal of Molecular Sciences
Summary:
A 78-year-old patient with chronic Crohn’s received one treatment of Stem Cell Educator therapy using umbilical cord blood stem cells. Within weeks, bowel movements normalized and abdominal pain disappeared. Follow-up colonoscopies at 5 weeks and 6 months showed healed intestinal lining and no active inflammation. Blood tests confirmed major drops in inflammatory markers, and CT imaging revealed full mucosal recovery.
2025 – MSC Therapy for Perianal Fistulizing Crohn’s (Meta-Analysis)
Title: Efficacy of mesenchymal stem cell-based therapies in the treatment of perianal fistulizing Crohn’s disease: a systematic review and meta-analysis
Date: March 28, 2025
Link: Stem Cell Research & Therapy
Summary:
This review of 25 studies involving ~600 patients found that 58% of those treated with MSCs achieved complete fistula closure by 6 months — substantially higher than control groups. No increase in adverse events was noted, confirming strong safety and meaningful clinical improvement in a difficult-to-treat Crohn’s complication.
2024 – Comprehensive Review of Stem Cell Therapy for Crohn’s
Title: Safety and efficacy of stem cell therapy for Crohn’s disease: an umbrella review of systematic reviews
Date: September 30, 2024
Link: PubMed Central
Summary:
Researchers pooled 16 previous reviews of stem-cell-based therapy in Crohn’s disease. Results showed higher remission rates and improved fistula healing compared with conventional treatments. Importantly, MSC therapy did not increase infection or adverse event risks, suggesting it may be a reliable adjunctive treatment in complex cases.
2024 – Umbilical Cord MSCs in Moderate-to-Severe Crohn’s
Title: Therapeutic potential of human umbilical cord-derived mesenchymal stem cells in Crohn’s disease
Date: April 25, 2024
Link: News-Medical Summary / Research Report
Summary:
In a Chinese pilot study, patients with active Crohn’s unresponsive to standard therapy received local stem-cell injections during colonoscopy plus IV infusion. By 12 weeks, ~50% showed visible ulcer healing and some achieved complete mucosal repair. At 24 weeks, many reached clinical remission with no major side effects, suggesting MSC therapy may restore gut integrity safely.
Could Regenerative Medicine Be Right for You?
You may want to consider regenerative therapy if you:
- Experience frequent or severe flare-ups despite medication
- Struggle with side effects from steroids or biologics
- Want to explore non-surgical, restorative approaches
- Seek a therapy that focuses on repairing intestinal tissue, not just controlling symptoms
At Stemedix, our team carefully reviews your medical history and current therapies to determine if MSC-based regenerative treatment may complement your ongoing Crohn’s care.
Medical Disclaimer
This content is for educational purposes only and does not replace medical advice.
Stem-cell and regenerative therapies for Crohn’s disease are investigational and not FDA-approved.
Results vary; consult a licensed medical professional before undergoing treatment.
References
- Clinical, immunological, and radiographic improvements after Stem Cell Educator therapy. Int J Mol Sci, 2025.
- MSC therapy for perianal fistulizing Crohn’s: meta-analysis. Stem Cell Res Ther, 2025.
- Umbrella review: safety and efficacy of stem cell therapy for Crohn’s. PubMed Central, 2024.
- Therapeutic potential of UC-MSCs in Crohn’s disease. News-Medical Report, 2024.
by Shoot To Thrill Media | Oct 21, 2025 | Wrist & Hand Pain
Medical Review: Dr. Gerald Mastaw, MD – Board-Certified Physician
Last Updated: October 2025
What Causes Wrist & Hand Pain?
Your wrists and hands contain a complex network of joints, tendons, ligaments, and nerves that allow for precise movement and strength. Because they’re used constantly, typing, lifting, gripping, they’re also prone to strain, inflammation, and degeneration over time.
Common Causes
- Carpal tunnel syndrome (nerve compression in the wrist)
- Tendinitis or tenosynovitis (inflammation of tendons)
- Arthritis (wear of cartilage in small joints)
- Ligament or tendon tears
- Overuse or repetitive stress injuries
- Post-traumatic pain or stiffness after injury or surgery
Typical Symptoms
- Pain or stiffness in the wrist, thumb, or fingers
- Numbness or tingling (especially at night or with typing)
- Swelling or tenderness
- Weak grip or difficulty opening jars or holding objects
- Clicking, popping, or grinding with movement
These symptoms can worsen with daily use, making even simple tasks uncomfortable.
Traditional Treatment Options
Most people start with conservative care to reduce inflammation and restore motion.
Common approaches include:
- Rest or wrist splints
- Ice and anti-inflammatory medications
- Cortisone injections for short-term relief
- Physical or occupational therapy
- Ergonomic adjustments for repetitive motion
When these methods fail, some patients are advised to consider surgery for severe arthritis, ligament tears, or carpal tunnel decompression.
However, surgery can involve downtime, stiffness, and incomplete recovery, especially in older or highly active individuals.
Regenerative Medicine for Wrist & Hand Healing
Regenerative medicine offers a biologically driven approach to healing. Instead of masking symptoms, treatments like platelet-rich plasma (PRP) and umbilical cord tissue–derived mesenchymal stem cells (UCT-MSCs) may help repair and regenerate damaged tissues at a cellular level.
How It Works
- PRP Therapy: Uses concentrated growth factors from your own blood to stimulate healing in tendons, ligaments, and joint tissues.
- UCT-MSC Therapy: Delivers stem-cell-derived signaling molecules that reduce inflammation, modulate immune activity, and encourage tissue regeneration.
- These biologics can be injected precisely into the wrist or affected joints under ultrasound guidance.
Potential Benefits
- Reduced pain and swelling
- Improved grip strength and mobility
- Better tissue repair and flexibility
- Reduced reliance on steroids or pain medications
- Potential to delay or avoid surgery
Note: PRP and MSC-based therapies are not FDA-approved for wrist or hand conditions. They are considered investigational, though increasing clinical evidence supports their safety and therapeutic potential.
Recent Clinical Studies on Regenerative Treatments for Wrist & Hand Conditions
2025 – MSCs for Hand Osteoarthritis
Title: Umbilical cord-derived mesenchymal stem cell injections improve hand function and reduce pain in osteoarthritis: a phase I/II clinical trial
Date: January 2025
Link: PubMed Central
Summary:
In this early-phase human study, patients with painful hand and thumb osteoarthritis received a single injection of umbilical cord–derived MSCs. Over 12 months, they experienced significant improvements in hand pain (VAS) and function (DASH scores) with no serious adverse effects. MRI scans showed reduced inflammation in joint tissues. The authors concluded that UCT-MSCs are a safe and promising therapy for small-joint osteoarthritis of the hands.
2024 – PRP vs Corticosteroids for Wrist Tendinitis
Title: Efficacy of platelet-rich plasma versus corticosteroid injection in chronic wrist flexor and extensor tendinopathy: a randomized controlled trial
Date: October 2024
Link: Journal of Orthopaedic Surgery and Research
Summary:
This RCT compared PRP and steroid injections in 80 patients with chronic wrist tendinitis. Both groups improved, but PRP patients had greater pain relief and functional recovery at 6 months. Ultrasound follow-up showed better tendon thickness and vascularity in the PRP group, indicating true tissue repair rather than just symptom relief.
2023 – MSC Exosomes for Carpal Tunnel Syndrome
Title: Clinical evaluation of umbilical cord mesenchymal stem cell–derived exosomes for mild-to-moderate carpal tunnel syndrome
Date: July 2023
Link: Frontiers in Neurology
Summary:
In this first-of-its-kind pilot trial, 25 patients with carpal tunnel syndrome received a single ultrasound-guided injection of MSC-derived exosomes. By 3 months, participants reported significant pain reduction and improved nerve conduction velocity, with no safety issues. Researchers concluded that exosome therapy was safe and may enhance nerve recovery in carpal tunnel syndrome.
2022 – PRP for Thumb (CMC) Osteoarthritis
Title: Platelet-rich plasma injection for first carpometacarpal (CMC) joint osteoarthritis: a randomized controlled trial
Date: February 2022
Link: Journal of Hand Surgery (European Volume)
Summary:
Fifty patients with thumb base arthritis received either PRP or hyaluronic acid injections. Both groups improved, but PRP patients reported stronger grip, less pain, and better hand function at 6 months. The authors noted PRP is a safe, non-surgical alternative that provides sustained pain relief for thumb arthritis.
2021 – PRP for Chronic Wrist Ligament Injuries
Title: Autologous platelet-rich plasma in chronic wrist ligament injury: a prospective clinical study
Date: August 2021
Link: BMC Musculoskeletal Disorders
Summary:
Patients with chronic scapholunate ligament injuries (a common cause of wrist instability) received PRP injections under fluoroscopic guidance. Over 12 months, they showed improved grip strength, stability, and reduced pain, without surgical intervention. Imaging demonstrated ligament thickening and improved continuity in several cases.
Is Regenerative Care Right for You?
You may be a good candidate if you:
- Have chronic wrist or hand pain that hasn’t improved with standard care
- Suffer from carpal tunnel, arthritis, or tendon inflammation
- Want to avoid surgery or long recovery times
- Prefer a natural, cell-based therapy focused on healing
At Stemedix, our team evaluates your history, imaging, and goals to determine whether PRP, stem-cell-derived biologics, or a combination approach may best support your recovery.
Medical Disclaimer
This information is for educational purposes only and is not medical advice.
PRP and stem cell therapies for wrist and hand pain are investigational and not FDA-approved.
Individual results vary; always consult a licensed healthcare provider.
References
- Umbilical cord-derived mesenchymal stem cells for hand osteoarthritis. PubMed Central, 2025.
- PRP vs corticosteroid injection in wrist tendinopathy: RCT. Journal of Orthopaedic Surgery and Research, 2024.
- MSC-derived exosomes for carpal tunnel syndrome. Frontiers in Neurology, 2023.
- PRP for first carpometacarpal (thumb) arthritis: RCT. Journal of Hand Surgery (European Volume), 2022.
- PRP in chronic wrist ligament injury: prospective study. BMC Musculoskeletal Disorders, 2021.
by Shoot To Thrill Media | Oct 21, 2025 | Post-Stroke Syndrome
Medical Review: Dr. Gerald Mastaw, MD – Board-Certified Physician
Last Updated: October 2025
What Is Post-Stroke Syndrome?
Post-Stroke Syndrome refers to the lasting physical, cognitive, and emotional effects that can occur after a stroke.
While some people recover rapidly, others may experience ongoing challenges that persist for months or even years.
Common Symptoms Include:
- Muscle weakness or stiffness
- Difficulty speaking or understanding words
- Memory or concentration problems
- Persistent fatigue or low energy
- Mood changes such as depression or anxiety
- Chronic pain, numbness, or tingling sensations
These symptoms vary in severity from person to person, but they can significantly impact independence, mobility, and quality of life.
Conventional Treatment Approaches
Traditional stroke rehabilitation focuses on restoring function and preventing complications, but progress often slows after the first few months.
Treatment typically combines physical, occupational, and speech therapy along with symptom management.
Common Treatments Include:
- Physical therapy – Improves strength, coordination, and balance
- Occupational therapy – Helps patients relearn everyday skills
- Speech therapy – Assists with communication and swallowing difficulties
- Medications – Manage depression, spasticity, pain, or sleep disturbances
- Psychological support – Addresses mood and cognitive changes
While these therapies remain essential, some patients reach a plateau in recovery. This is where regenerative medicine may provide new potential for continued improvement.
Regenerative Medicine: Supporting Brain Repair
Regenerative medicine aims to activate the body’s own repair mechanisms to restore tissue health and function.
One of the most promising areas involves umbilical cord tissue-derived mesenchymal stem cells (UCT-MSCs), which are being studied for their ability to support neural recovery after stroke.
How UCT-MSC Therapy May Help
Research suggests that UCT-MSCs may:
- Protect and repair damaged brain tissue
- Reduce inflammation that worsens neurological injury
- Enhance communication between surviving nerve cells
- Support motor and cognitive recovery
- Improve overall energy, focus, and coordination
These cells release natural growth factors that can help create a more favorable environment for healing, even in chronic post-stroke phases where traditional therapies have plateaued.
Important Note:
Stem cell therapy for stroke recovery is investigational and not FDA-approved. However, early research suggests that biologic and cellular approaches may help improve quality of life and function for some patients.
Recent Clinical Studies on Regenerative Medicine for Stroke Recovery
2025 – Cord Blood Infusion for Acute Ischemic Stroke
Title: Allogeneic Human Umbilical Cord Blood for Acute Ischemic Stroke: Phase I Clinical Trial
Journal: PubMed – Full Text
Summary:
In this Phase I study, six adults received umbilical cord blood infusions within 9 days of stroke onset.
The treatment was well-tolerated with no serious adverse events.
Over the following year, patients showed steady improvement in movement, speech, and daily function, reflected by better neurological and independence scores.
Researchers concluded that cord blood infusions are safe and may enhance recovery after ischemic stroke.
2023 – UC-MSC Therapy in Chronic Stroke Patients
Title: Outcomes of Mesenchymal Stem Cell Transplantation in Five Stroke Patients
Journal: Frontiers in Medicine – Full Text
Summary:
Five adults with long-term post-stroke disability received umbilical cord MSC infusions.
All showed notable recovery in strength, coordination, and mobility—even years after their strokes.
One participant regained arm and hand movement after years of paralysis.
No serious side effects were reported.
The study highlighted that regenerative therapy may help restore function beyond the typical rehabilitation window.
2022 – Direct Brain Injection of Placenta-Derived MSC Exosomes
Title: Safety of Intraparenchymal Injection of Allogeneic Placenta MSC-Derived Exosomes in Severe Stroke Patients: Pilot Randomized Trial
Journal: Frontiers in Neurology – Full Text
Summary:
In this small pilot trial, five patients with severe brain swelling received exosome injections (healing nanoparticles from placenta MSCs) during surgery.
No bleeding, swelling, or immune reactions occurred.
Some patients showed early neurological improvement.
The findings confirmed procedure safety and laid the groundwork for larger studies on cell-free regenerative stroke therapies.
2021 – Cord Blood Monocyte Infusion Restores Motor Function
Title: Complete Restoration of Motor Function in Acute Cerebral Stroke Treated with Allogeneic Cord Blood Monocytes: Phase I Trial
Journal: PubMed – Full Text
Summary:
A 51-year-old man who was nearly paralyzed after a major stroke received cord blood monocyte infusion.
Over one year, he regained full independence and movement, with imaging showing shrinkage of the brain injury area.
No adverse reactions were seen, suggesting cord-derived cells can enhance brain repair safely and effectively.
2021 – UC-MSC Therapy After Ischemic Stroke
Title: Treatment of Acute Ischemic Stroke by Minimally Manipulated Umbilical Cord-Derived MSC Transplantation: Case Report
Journal: PubMed – Full Text
Summary:
A 45-year-old patient received three UC-MSC infusions following stroke.
Over the next year, he experienced steady recovery in speech, strength, and independence, with brain imaging confirming reduced injury size.
The therapy was safe and well tolerated, and his neurological condition improved to near-normal levels.
This case demonstrates the potential of UCT-MSC therapy to support functional recovery after stroke.
Is Regenerative Therapy Right for You?
Stem cell and regenerative therapies may be worth exploring if you:
- Have persistent weakness, speech issues, or fatigue after stroke
- Have plateaued in traditional rehabilitation
- Are seeking a non-surgical, biologic option to support brain recovery
- Want to learn about evidence-informed therapies that promote neurorepair
At Stemedix, we provide comprehensive evaluations to determine whether regenerative care could complement your recovery plan. Our focus is on helping patients regain independence and enhance quality of life through advanced, science-based approaches.
Medical Disclaimer
This page is for educational purposes only and does not replace professional medical advice.
Stem cell and exosome therapies for post-stroke recovery are not FDA-approved, and results vary by individual.
Always consult your healthcare provider before pursuing any investigational treatment.
References
- Lee H. et al. Allogeneic Human Umbilical Cord Blood for Acute Ischemic Stroke. PubMed., 2025. Full Text
- Park M. et al. Outcomes of Mesenchymal Stem Cell Transplantation in Chronic Stroke. Front Med., 2023. Full Text
- Farid H. et al. Placenta MSC-Derived Exosomes for Severe Stroke. Front Neurol., 2022. Full Text
- Ouyang Q. et al. Cord Blood Monocyte Infusion in Acute Cerebral Stroke. PubMed., 2021. Full Text
- Zhang Y. et al. UC-MSC Therapy for Ischemic Stroke. PubMed., 2021. Full Text
by Shoot To Thrill Media | Oct 21, 2025 | Peripheral Neuropathy
Medical Review: Dr. Gerald Mastaw, MD – Board-Certified Physician
Last Updated: October 2025
What Is Peripheral Neuropathy?
Peripheral neuropathy occurs when the peripheral nerves, the network that carries signals between your brain, spinal cord, and the rest of your body, become damaged or dysfunctional.
These nerves control sensation, movement, and involuntary functions such as blood pressure, digestion, and heart rate.
When they’re injured, communication between the brain and the body becomes disrupted, leading to symptoms such as:
- Numbness or tingling in the hands or feet
- Burning or stabbing pain
- Muscle weakness or loss of coordination
- Heightened sensitivity to touch
- Balance problems or difficulty walking
Common Causes
While diabetes is the most frequent cause, peripheral neuropathy can also result from:
- Physical injury or trauma
- Autoimmune disorders (like lupus or Guillain-Barré)
- Infections such as shingles or Lyme disease
- Vitamin deficiencies (especially B vitamins)
- Certain medications (including chemotherapy drugs)
- Exposure to toxins or heavy metals
Traditional Treatment Approaches
Conventional therapies primarily manage symptoms rather than repairing nerve damage.
While they can provide meaningful relief, many patients continue to experience chronic discomfort or numbness.
Common Treatment Options Include:
- Medications: Anti-seizure drugs or antidepressants used to reduce nerve pain
- Topical creams and patches: Such as capsaicin or lidocaine for localized pain
- Physical therapy: To improve strength, flexibility, and coordination
- Blood sugar management: Essential for diabetic patients
- Surgery: In select cases where nerve compression is the cause
These methods can ease discomfort but generally do not address the root cause, the loss or dysfunction of nerve cells.
Regenerative Medicine: A New Approach to Nerve Repair
Regenerative medicine represents a different strategy: it seeks to restore and protect nerve health by activating the body’s own healing potential.
Among the most studied options are umbilical cord tissue-derived mesenchymal stem cells (UCT-MSCs), young, dynamic cells capable of releasing natural growth factors that encourage nerve regeneration and reduce inflammation.
How UCT-MSC Therapy May Help
- Promote regeneration of damaged or degenerated nerve fibers
- Calm inflammation around affected nerves
- Enhance circulation and oxygen delivery to nerve tissue
- Reduce pain, tingling, and numbness over time
Unlike standard medications, these biologic therapies aim to support underlying repair processes, helping patients experience improved sensation, balance, and mobility as part of a long-term wellness strategy.
Recent Clinical Studies on Regenerative Medicine for Peripheral Neuropathy
2024 – Meta-Analysis of Stem Cell Therapy for Diabetic Neuropathy
Title: Human Studies of the Efficacy and Safety of Stem Cells in the Treatment of Diabetic Peripheral Neuropathy: Systematic Review and Meta-Analysis
Journal: Frontiers in Endocrinology – Full Text
Summary:
This 2024 meta-analysis reviewed multiple human clinical trials using umbilical cord-derived and other MSC-based therapies for diabetic neuropathy.
Results showed that treated patients had significantly faster nerve conduction, better sensory scores, and lower neuropathy severity compared to controls.
Adverse events were minimal—mostly mild, short-term injection-site discomfort.
The analysis concluded that MSC therapy may effectively promote nerve repair and symptom improvement with a strong safety profile.
2024 – Combination Therapy Reduces Neuropathy Risk Long-Term
Title: Bone Marrow and Umbilical Cord MSC Combination Therapy in Type 2 Diabetes: 8-Year Follow-Up
Journal: Stem Cell Research & Therapy – Full Text
Summary:
In this long-term randomized study, diabetic patients who received regenerative cell therapy—including UCT-MSCs—had a dramatically lower risk of developing peripheral neuropathy.
After 8 years, only 10% of treated patients developed neuropathy compared to 48% in the control group.
The authors concluded that stem cell therapy may offer protective effects for nerve health, helping prevent or delay neuropathy in diabetes.
2022 – Dual IV and Topical UCT-MSC Therapy for Diabetic Foot Ulcers
Title: Topical and Intravenous Administration of UC-MSCs in Diabetic Foot Ulcer and Peripheral Arterial Disease: Phase I Pilot Study
Journal: Stem Cell Research & Therapy – Full Text
Summary:
In this Phase I trial, 14 patients with diabetic foot ulcers and associated neuropathy received both intravenous and local UC-MSC therapy.
The treatment was safe and well tolerated, with only mild transient fever in two cases.
Within six weeks, over 95% wound closure was observed, along with improved circulation and reduced limb pain.
Researchers concluded that UCT-MSC therapy enhanced healing, blood flow, and nerve comfort in patients with severe neuropathic complications.
Is Regenerative Therapy Right for You?
You may want to explore regenerative care if you:
- Have diabetic or idiopathic neuropathy not improving with conventional treatments
- Want to reduce reliance on long-term pain medications
- Are looking for a minimally invasive option that targets nerve healing
- Seek to prevent further nerve deterioration and support better function
At Stemedix, we specialize in evidence-informed regenerative therapies designed to restore nerve health and improve quality of life. Each plan is personalized to your condition, goals, and medical background.
Medical Disclaimer
This information is provided for educational purposes and does not replace professional medical advice.
Stem cell and regenerative treatments for peripheral neuropathy are investigational and not FDA-approved for this indication.
Always consult with a qualified healthcare professional to determine whether regenerative therapy is appropriate for you.
References
- Li J. et al. Efficacy and Safety of Stem Cell Therapy in Diabetic Neuropathy: Meta-Analysis. Front Endocrinol., 2024. Full Text
- Zhao L. et al. Combination Cell Therapy Reduces Neuropathy Risk in Type 2 Diabetes. Stem Cell Res Ther., 2024. Full Text
- Chen H. et al. Intravenous and Topical UC-MSCs for Diabetic Foot Ulcer & Neuropathy. Stem Cell Res Ther., 2022. Full Text
by Shoot To Thrill Media | Oct 21, 2025 | Parkinson’s Disease
Medical Review: Dr. Gerald Mastaw, MD – Board-Certified Physician
Last Updated: October 2025
What Is Parkinson’s Disease?
Parkinson’s disease is a progressive neurodegenerative disorder that affects movement, balance, and coordination.
It occurs when the brain’s dopamine-producing neurons, located in an area called the substantia nigra, break down over time.
Dopamine acts as a chemical messenger that allows smooth, controlled movement.
When dopamine levels decline, the communication between nerve cells is disrupted, leading to the hallmark symptoms of Parkinson’s.
Common Symptoms
- Tremors or shaking (often in the hands)
- Muscle stiffness or rigidity
- Slowed movement (bradykinesia)
- Difficulty with balance, posture, or walking
- Changes in facial expression or speech
As Parkinson’s progresses, some individuals may also experience sleep difficulties, fatigue, memory or mood changes, and reduced fine motor control.
Conventional Care Approaches
Current Parkinson’s treatments primarily focus on symptom management rather than reversing the underlying neuronal loss.
Although these therapies can significantly improve quality of life, they do not halt disease progression.
Common Treatment Options
- Medication:
Drugs such as levodopa and carbidopa temporarily boost dopamine activity, improving mobility and tremor control.
- Deep Brain Stimulation (DBS):
A surgical procedure that sends gentle electrical impulses to motor areas of the brain to help reduce movement symptoms.
- Physical and Occupational Therapy:
Structured exercise programs that support balance, strength, and coordination.
Over time, medications may lose effectiveness or cause side effects like involuntary movements (dyskinesias), prompting exploration of new therapeutic directions.
Regenerative Medicine: A New Direction for Parkinson’s Care
Regenerative medicine seeks to restore function by supporting the body’s natural repair and renewal processes, rather than masking symptoms.
Among the most promising biologic approaches are umbilical cord tissue-derived mesenchymal stem cells (UCT-MSCs) and other cell-based neuroregenerative therapies.
How Regenerative Therapies May Help
- Protect existing neurons from further degeneration
- Reduce inflammation in the central nervous system
- Release neurotrophic (healing) growth factors that support nerve cell health
- Promote repair of damaged tissue and cellular communication pathways
Researchers are also studying ways to replace lost dopamine-producing neurons using specialized stem cells, offering hope for future functional restoration.
Recent Clinical Studies in Regenerative Parkinson’s Research
2025 – Embryonic Stem Cell-Derived Dopamine Neurons
Title: Phase I Trial of hES Cell-Derived Dopaminergic Neurons for Parkinson’s Disease
Journal: Nature – Full Text
Summary:
Twelve patients received bemdaneprocel, a therapy made from laboratory-grown dopamine neurons derived from human embryonic stem cells.
After 18 months, imaging confirmed that the transplanted cells survived and produced dopamine without causing immune reactions or dyskinesias.
Patients receiving higher doses improved their motor scores by an average of 23 points on the UPDRS scale, showing meaningful movement recovery.
This groundbreaking study demonstrated that cell replacement therapy can safely restore dopamine activity in the human brain.
2025 – iPSC-Derived Neuron Transplants
Title: Phase I/II Trial of iPSC-Derived Dopaminergic Cells for Parkinson’s Disease
Journal: Nature / PubMed – Full Text
Summary:
In Japan, seven patients received induced pluripotent stem cell (iPSC)-derived dopamine neuron precursors transplanted into both sides of the brain.
Over two years, the grafts were well-tolerated with no serious complications.
Patients in the higher-dose group improved their motor scores by 30–50%, and PET scans confirmed increased dopamine activity where the cells were placed.
These findings support that stem-cell-based neuron therapies are safe and biologically active in human Parkinson’s patients.
What About Umbilical Cord-Derived Stem Cells (UCT-MSCs)?
While the above studies focus on neuron replacement, umbilical cord tissue-derived MSCs are being explored for their immunomodulatory and neuroprotective effects, helping calm inflammation, protect remaining neurons, and improve cellular signaling.
Early research and case reports suggest UCT-MSCs may help reduce neuroinflammation, stabilize symptoms, and enhance overall brain function by supporting the neural environment, though more large-scale studies are needed.
Is Regenerative Therapy Right for You?
Stem cell and regenerative approaches for Parkinson’s are still considered investigational and are not FDA-approved.
However, some patients choose to explore these options under experienced medical supervision as part of a comprehensive care plan.
You may consider learning more if you:
- Wish to explore biologic or cell-based options to complement current therapy
- Want to support neuroprotection and reduce inflammation naturally
- Are seeking to participate in or learn from ongoing research efforts
At Stemedix, we help patients understand emerging regenerative options, review available clinical evidence, and connect with safe, evidence-informed pathways for neurological wellness.
Medical Disclaimer
This material is for educational purposes only and does not replace medical advice.
Stem cell and regenerative treatments for Parkinson’s disease are not FDA-approved, and outcomes vary.
Always consult a qualified healthcare provider before pursuing investigational therapies.
References
- Schweitzer J. et al. Phase I Trial of hES Cell-Derived Dopaminergic Neurons for Parkinson’s Disease. Nature., 2025. Full Text
- Takahashi J. et al. Phase I/II iPSC-Derived Dopaminergic Cell Transplants for Parkinson’s. Nature / PubMed., 2025. Full Text
St. Petersburg, Florida
